Brineura Cleared By England's NICE For Ultra-Rare Batten Disease
Executive Summary
NICE has recommended BioMarin’s Brineura for use in the National Health Service in England after a managed access deal and product pricing were agreed between BioMarin and NHS England. Final details of the deal are expected next month.
You may also be interested in...
Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
Denmark's IO Vaccine Biotech Attracts Investor Interest
Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.
COVID-19 Could Change Attitudes To Flu, Bolster Xofluza
Roche’s first-in-class one-dose antiviral Xofluza has been approved for marketing in the EU to treat influenza in patients aged 12 years or over, and for post-exposure prophylaxis.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: